A Phase I, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess Safety,Tolerability, Pharmacokinetics and Efficacy of MEDI-578, an Anti-NGF Monoclonal Antibody, After Single Ascending Doses in Male and Non-fertile Female Patients With Painful Osteoarthritis of the Knee.

Trial Profile

A Phase I, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess Safety,Tolerability, Pharmacokinetics and Efficacy of MEDI-578, an Anti-NGF Monoclonal Antibody, After Single Ascending Doses in Male and Non-fertile Female Patients With Painful Osteoarthritis of the Knee.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 28 Jan 2013

At a glance

  • Drugs MEDI 578 (Primary)
  • Indications Musculoskeletal pain; Osteoarthritis
  • Focus Adverse reactions
  • Most Recent Events

    • 26 Nov 2010 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
    • 26 Nov 2010 Planned end date changed from 1 Oct 2010 to 1 Sep 2010 as reported by ClinicalTrials.gov.
    • 13 Jul 2010 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top